为更好地回报广大投资者，在符合公司利润分配政策和长远发展的前提下， 公司拟定的 2025 年半年度利润分配预案为：以实施 2025 年半年度权益分派时股 权登记日登记的总股本扣除公司回购专用证券账户中股份数量为基数，向全体股 东每 10 股派发现金分红 6 元（含税），本次利润分配不送红股，不以资本公积 金转增股本。 鉴于公司正在中国证券登记结算有限责任公司深圳分公司办理 2021 年限制 性股票激励计划第三个限售期对应的第一类限制性股票 195,000 股的回购注销手 续，暂以截至目前公司总股本 209,092,000 股扣除公司回购专用证券账户中股份 数 5,699,731 股及正在回购注销的第一类限制性股票 195,000 股后的股本 203,197,269 股为基数，以此计算合计派发现金红利 121,918,361.40 元（含税）。 从方案公告日至实施利润分配方案的股权登记日期间股本发生变动的，以实 施利润分配方案的股权登记日可参与利润分配的总股本为基数，按照现金分红分 配比例不变的原则对现金分红总额进行调整。 证券代码：301087 证券简称：可孚医疗 公告编号：2025-061 可孚医疗科技股份 ...

可孚医疗科技股份有限公司 2025 年半年度报告全文 可孚医疗科技股份有限公司 2025 年半年度报告 2025-059 2025 年 8 月 1 可孚医疗科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人张敏、主管会计工作负责人陈望朋及会计机构负责人(会计主 管人员)申佩声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中如有涉及未来计划、发展战略等前瞻性陈述的内容，均不构成公 司对投资者的实质承诺，投资者及相关人士均应当对此保持足够的风险认识， 并且应当理解计划、预测与承诺之间的差异。 公司在本报告第三节"管理层讨论与分析"之"十 公司面临的风险和应 对措施"部分，详细描述了公司经营中可能存在的风险及应对措施，敬请投 资者关注相关内容。 公司经本次董事会审议通过的利润分配预案为：以实施 2025 年半年度权 益分派时股权登记日登记的总股本扣除公司回购专用证券账 ...

Group 1 - Since August, nearly 20 A-share listed companies have announced plans to list in Hong Kong, with companies like Luxshare Precision and Victory Technology formally submitting H-share listing applications [1][6] - The main motivations for these companies to pursue a Hong Kong listing include expanding international strategies, optimizing overseas business layouts, enhancing brand recognition, and improving overseas financing capabilities [1][5] Group 2 - The recent A-share companies planning to list in Hong Kong span various industries, including electronics, machinery, pharmaceuticals, food and beverage, chemicals, and media, with the electronics sector being the most concentrated [5][6] - Notable companies in the electronics sector include Huajin Technology, Chipsea Technologies, and Luxshare Precision, while the pharmaceutical sector features companies like Sinovac Biotech and Kefu Medical [5][6] Group 3 - Industry analysts suggest that sectors with strong global attributes, such as resource energy, equipment manufacturing, and pharmaceutical innovation, are more likely to benefit from the "A+H" listing strategy [5][7] - For instance, Sinovac Biotech aims to deepen its "innovation + internationalization" strategy through its Hong Kong listing, which will accelerate overseas business development and enhance its international brand image [5][6] Group 4 - Companies in the electronics industry, such as Jinghe Integration and Huajin Technology, believe that listing in Hong Kong will help them expand overseas customer bases and optimize investment layouts [6][7] - Leading companies like Luxshare Precision, with a market value exceeding 300 billion, plan to use the funds raised from their IPO for capacity expansion and technological research [6][7] Group 5 - Market analysts indicate that large state-owned enterprises and industry leaders prefer the "A+H" model to support long-term international financing needs, while mid-sized growth companies can enhance international investor recognition through this model [7] - The new regulations effective from August 4 at the Hong Kong Stock Exchange have improved the pricing and public market rules for initial public offerings, which is expected to further encourage A-share companies to list in Hong Kong [7]

Investment Rating - The report maintains a "Buy" rating for the agriculture, forestry, animal husbandry, and fishery sector [4] Core Viewpoints - The report indicates that the destocking phase for live pigs is nearing its end, with a focus on the effects of a new round of pork reserves [1] - The report highlights a recent decline in pork prices, with the average price for live pigs at 13.75 yuan/kg, down 0.07% week-on-week, and a significant drop in the price of piglets by 3.78% to 27.78 yuan/kg [1][22] - The report notes an increase in the average weight of slaughtered pigs, which is expected to stabilize prices as the government resumes pork reserves to boost market sentiment [1][22] Summary by Sections 1. Market Overview - The agriculture, forestry, animal husbandry, and fishery sector underperformed compared to the broader market, with the sector index rising by 3.72% while the Shanghai Composite Index rose by 3.49% [13] - The report provides a detailed performance breakdown of sub-sectors, with livestock farming showing a 4.31% increase [13] 2. Key Data Tracking 2.1 Live Pigs - The average weight of slaughtered pigs is reported at 127.98 kg, showing a slight increase of 0.16 kg week-on-week [22] - The national frozen meat storage capacity rate is at 14.77%, up 0.1 percentage points [22] 2.2 White Feather Broilers - The price of white feather broilers increased to 7.33 yuan/kg, up 1.81% week-on-week, while chick prices remained stable at 3.58 yuan each [31] 2.3 Yellow Feather Broilers - The price of medium-speed chickens rose to 6.34 yuan/jin, reflecting a 4.97% increase, driven by rising demand post-typhoon [40] 2.4 Feed Sector - The report notes a decline in the prices of corn, wheat, and soybean meal, with corn averaging 2373.53 yuan/ton, down 0.86% week-on-week [2][45] 2.5 Major Agricultural Products - The price of natural rubber fell to 15640 yuan/ton, down 0.89% week-on-week, with inventory levels decreasing slightly [60] 3. Investment Recommendations - The report recommends focusing on the pig farming sector, suggesting that the long-term profitability cycle is beginning to improve, with specific companies highlighted for investment: Muyuan Foods, Wens Foodstuff Group, Juxing Agriculture, and Shennong Group [3] - It also suggests monitoring the feed and animal health sectors, particularly companies like Haida Group and Ruipu Biological, as demand is expected to rise [3] - In the planting chain, the report identifies investment opportunities in companies such as Suqian Agricultural Development and Beidahuang Group due to favorable grain price trends [3]

Group 1 - A-share listed companies are increasingly pursuing dual listings in Hong Kong, with Luxshare Precision recently submitting an application for H-share issuance [1][3] - Since 2025, 11 A-share companies have successfully listed in Hong Kong, with over 30 more planning to do so, indicating a growing trend [3] - Companies like Changchun High-tech aim to enhance their global strategy and international brand image through H-share issuance in Hong Kong [3] Group 2 - The IPO market in Hong Kong has been active, with 53 companies successfully listing on the main board in the first seven months, raising HKD 127 billion, a sixfold increase compared to the previous year [3] - The influx of international long-term capital is notable, with an average of 30 institutional investors participating in each IPO, and a significant increase in participation from sovereign funds in the Middle East and Northern Europe [3] - The recent launch of the "Special Line for Science and Technology Companies" by the Hong Kong Stock Exchange is expected to strengthen the ecosystem for innovative enterprises [3] - Deloitte China forecasts that there could be 80 new IPOs in Hong Kong this year, raising between HKD 130 billion to 150 billion [3]

Core Viewpoint - A-share leading companies are increasingly pursuing dual listings in Hong Kong, driven by globalization strategies and supportive regulatory reforms in the Hong Kong market [1][2]. Group 1: Market Trends - Several A-share companies, including Luxshare Precision, have submitted applications for H-share listings, indicating a trend towards "A+H" dual listings [1]. - In 2025, 11 A-share companies have already listed in Hong Kong, with over 30 more planning to do so, reflecting a growing pipeline of companies seeking international capital [2]. - The Hong Kong IPO market has seen significant activity, with 53 companies successfully listing and raising HKD 127 billion in the first seven months of the year, a sixfold increase compared to the previous year [2]. Group 2: Regulatory Environment - The China Securities Regulatory Commission has introduced five measures to support mainland companies in listing in Hong Kong, including expedited approval processes for companies with market capitalizations over HKD 10 billion [4]. - The Hong Kong Stock Exchange has lowered the listing thresholds for A-share companies and introduced a "Specialized Technology Company" listing channel to facilitate listings for tech and biotech firms [4][5]. Group 3: Investment Dynamics - International long-term capital is increasingly flowing into Hong Kong IPOs, with an average of 30 institutional investors participating in each IPO, indicating strong global confidence in China's industrial upgrades and consumption potential [3]. - Deloitte estimates that there could be 80 new IPOs in Hong Kong this year, raising between HKD 130 billion and HKD 150 billion [6]. Group 4: Strategic Considerations for Companies - Companies looking to go public in Hong Kong should optimize their governance structures and ensure compliance with local regulations to enhance their chances of successful listings [6]. - The dual listing strategy is seen as a way to diversify funding sources, enhance international brand visibility, and mitigate market risks [2][4].

Core Viewpoint - The stock of Kefu Medical (301087) has experienced a decline in price and significant net outflow of funds, indicating potential challenges in market sentiment and performance [1][2]. Group 1: Stock Performance - As of August 22, 2025, Kefu Medical's stock closed at 40.71 yuan, down 1.19% with a turnover rate of 2.05% and a trading volume of 39,900 hands, resulting in a transaction amount of 162 million yuan [1]. - Over the past five days, the stock has shown a consistent downward trend, with a total net outflow of main funds amounting to 4,563.78 million yuan and a net inflow from retail investors of 4,375.03 million yuan [2]. Group 2: Financial Metrics - Kefu Medical's total market capitalization is 8.512 billion yuan, with a net asset value of 4.909 billion yuan and a net profit of 914.251 million yuan [3]. - The company's price-to-earnings ratio (P/E) stands at 23.28, significantly lower than the industry average of 77.99, indicating a potentially undervalued stock [3]. - The gross margin is reported at 52.17%, slightly above the industry average of 51.31%, while the net profit margin is 12.41%, higher than the industry average of 10.85% [3]. Group 3: Recent Ratings and Target Price - In the last 90 days, one institution has given a rating of "buy" for Kefu Medical, with an average target price set at 45.0 yuan [4].

Company Overview - Cofoe Medical Technology Co., Ltd. specializes in the research, production, sales, and service of medical devices, with key products including blood glucose systems, uric acid systems, blood pressure monitors, and various other medical instruments and supplies [2]. Financial Performance - In the first quarter of 2025, the company reported revenue of 738 million yuan, a year-on-year decrease of 8.59%, and a net profit of 91.43 million yuan, down 9.68%, with a gross profit margin of 52.17% [2]. Market Position - As of August 22, Cofoe Medical's stock closed at 40.71 yuan, down 1.19%, with a rolling price-to-earnings (PE) ratio of 28.19 times, and a total market capitalization of 8.512 billion yuan [1]. - The average PE ratio for the medical device industry is 56.95 times, with a median of 40.49 times, placing Cofoe Medical at the 55th position within the industry [1][3]. Capital Flow - On August 22, the company experienced a net outflow of 21.48 million yuan in principal funds, continuing a trend of outflows over the past five days, totaling 21.12 million yuan [1].

Group 1 - The stock price of Kefu Medical is reported at 41.20 yuan as of August 21, 2025, with a decrease of 1.90% compared to the previous trading day and a trading volume of 1.31 billion yuan [1] - Kefu Medical operates in the medical device sector, focusing on product research and sales in health monitoring, rehabilitation aids, and medical care [2] - A recent policy document issued by the National Health Commission and other departments emphasizes the enhancement of ear disease prevention and rehabilitation services, which may benefit Kefu Medical as a related concept stock [2] Group 2 - On August 21, there was a net outflow of 6.993 million yuan in main funds, while the net inflow over the past five days was 65.7165 million yuan [3]

Group 1 - The National Health Commission and three other departments have jointly issued guidelines to promote ear and hearing health, outlining seven main tasks [1] - The tasks include improving the service system and strengthening the construction of a four-level ear and hearing health work network at the national, provincial, municipal, and county levels [1] - The guidelines emphasize enhancing the prevention, screening, diagnosis, and rehabilitation services for key populations such as newborns, the elderly, and occupational groups [1] Group 2 - The guidelines call for strengthening standardized diagnosis and treatment of ear diseases, including the revision and formulation of relevant clinical diagnosis and treatment guidelines and technical specifications [1] - Related concept stocks in the A-share market include companies like Kefu Medical and Aipeng Medical [2]